AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.
ABTL0812 is currently in Phase 2b in in USA, Spain, France and Israel, in a double-blind placebo-controlled clinical trial in 130 patientens with metastatic pancreatic cancer.
ABTL0812 is currently in Phase 2b in in USA, Spain, France and Israel, in a double-blind placebo-controlled clinical trial in 130 patientens with metastatic pancreatic cancer.
Media Center
02.06.2023
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
29.12.2020
The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
